Media coverage about Array BioPharma (NASDAQ:ARRY) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Array BioPharma earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.5906713628641 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news stories that may have effected Accern’s scoring:

Shares of Array BioPharma (NASDAQ:ARRY) traded up $0.24 during midday trading on Thursday, hitting $12.97. The company had a trading volume of 1,692,156 shares, compared to its average volume of 3,814,163. The company has a market cap of $2,520.00, a PE ratio of -17.53 and a beta of 1.92. Array BioPharma has a 1-year low of $6.73 and a 1-year high of $13.40. The company has a current ratio of 5.43, a quick ratio of 5.43 and a debt-to-equity ratio of 0.54.

Array BioPharma (NASDAQ:ARRY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.22). The business had revenue of $29.75 million during the quarter, compared to analysts’ expectations of $33.74 million. Array BioPharma had a negative return on equity of 158.70% and a negative net margin of 89.30%. The firm’s quarterly revenue was down 24.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.20) EPS. analysts predict that Array BioPharma will post -0.99 EPS for the current fiscal year.

ARRY has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Array BioPharma in a report on Friday, September 8th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $14.00 target price on shares of Array BioPharma in a report on Monday, September 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $15.00 target price (up previously from $13.00) on shares of Array BioPharma in a report on Monday, September 11th. Cowen reiterated an “outperform” rating and issued a $15.00 target price (up previously from $14.00) on shares of Array BioPharma in a report on Monday, September 11th. Finally, Jefferies Group reiterated a “buy” rating and issued a $9.00 target price on shares of Array BioPharma in a report on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Array BioPharma currently has a consensus rating of “Buy” and an average target price of $14.10.

In related news, COO Andrew R. Robbins sold 282,874 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $10.72, for a total value of $3,032,409.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kyle Lefkoff sold 38,865 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $12.31, for a total value of $478,428.15. Following the completion of the sale, the director now directly owns 51,585 shares of the company’s stock, valued at approximately $635,011.35. The disclosure for this sale can be found here. In the last three months, insiders sold 1,141,410 shares of company stock valued at $12,412,464. 3.18% of the stock is currently owned by company insiders.

WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2017/12/28/array-biopharma-arry-getting-somewhat-favorable-press-coverage-report-shows.html.

About Array BioPharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Insider Buying and Selling by Quarter for Array BioPharma (NASDAQ:ARRY)

Receive News & Ratings for Array BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.